Global Aerosol Delivery Device Market - 2023-2030

Global Aerosol Delivery Device Market - 2023-2030

Global aerosol delivery device market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.

Aerosol is a suspension system of solid or liquid particles in a gas, typically air. It allows for medication to be delivered directly to the bloodstream through the lungs, without the complications of an IV, such as pain and injection site infection. This technique is primarily used for dosing medication for lung conditions, including asthma, but it may be beneficial for other therapies as well.

Market Dynamics: Drivers & Restraints

Growing Prevalence of Respiratory Diseases

The growing prevalence of respiratory diseases is expected to boost the global market growth during the forecast period. For instance, according to the World Health Organization (WHO) 2021 factsheet, COPD was among the third-leading reason of death globally, inducing 3.23 million casualties in 2020. More than 80% of these casualties happened in low and middle-income countries (LMIC).

Also, according to the Asthma and Allergy Foundation of America in March 2021, approximately 1 in 13 Americans had asthma, which was approximately 25 million individuals. Asthma is among the biggest contributors to this formation, involving children, adults, and geriatric individuals. The same reference remarked that almost 5 million American children had asthma.

Furthermore, the technological advancements, rise in research activities, increaseing investments and growing awareness are among the other additional factors boosting the global market growth during the forecast period.

Product Recalls

The increasing incidences of product recalls from market are expected to hamper the global market growth during the forecast period. for instance, Cipla Limited's wholly-owned associate, Cipla USA Inc., willingly recalled six batches of Albuterol Sulfate Inhalation Aerosol, 90 mcg (200 Metered Inhalation) manufactured in November 2021 to the consumer level with the knowledge of the U.S. Food and Drug Administration. Furthermore, stringent regulatory bodies, and high development costs are other additional factors hampering the global market growth during the forecast period.

Segment Analysis

The global aerosol delivery device market is segmented based on product, application, distribution channel and region.

Metered Dose Inhalers are Expected to Dominate Market

Owing to the increasing authorizations from the regulatory bodies for metered dose inhalers, the segment is expected to dominate the global market during the forecast period. For instance, in October 2021, BreatheSuite obtained 510(k) authorization from the FDA for its Metered-Dose Inhaler V1 device, which turns existing inhalers into smart inhalers for individuals with asthma and COPD. Moreover, in July 2023, Lupin's subsidiary unit Hormosan Pharma GmbH introduced a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Geographical Analysis

North America is Expected to Dominate the Global Market

Owing to the increasing approvals in North America the region is expected to dominate the global market during the forecast period. For instance, in July 2023, Viatris Inc., a multinational healthcare corporation, and Kindeva Drug Delivery introduced Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the foremost generic version of AstraZeneca's Symbicort with an Abbreviated New Drug Application (ANDA) authorized by the U.S. Food and Drug Administration (FDA). Moreover, in February 2020, The US Food and Drug Administration (FDA) authorized the foremost generic of ProAir HFA (albuterol sulfate) inhalation aerosol to treat or prevent bronchospasm in individuals of four years of age and older with reversible obstructive airway disease and prevention of exercise-induced bronchospasm in patients four years of age and older.

COVID-19 Impact Analysis

As SARS-CoV-2 directly targets the lungs and initiates lung damage, treating COVID-19 with inhalants presents multiple benefits over the enteral/parenteral administration. Inhaled drug delivery delivers higher drug concentrations, particularly in the pulmonary system. This allows the lessening of systemic side effects and delivers a quick clinical reaction, therefore, the pandemic has led to an increase in the demand for and investments in aerosol delivery devices, positively impacting the global market during the pandemic.

Market Segmentation

By Product
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers

By Applications
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Cystic Fibrosis
• Non-Respiratory Diseases

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In June 2022, United Therapeutics Corporation obtained FDA authorization for its Tyvaso DPI, an inhalation powder to treat pulmonary arterial hypertension and pulmonary hypertension linked with interstitial lung diseases.
• In January 2023, AstraZeneca obtained authorization from the U.S. Food and Drug Administration for Airsupra (albuterol and budesonide) inhalation aerosol. Airsupra strives to decrease the threat of asthma exacerbations in people aged 18 years and older.

Competitive Landscape

The major global players in the market include 3M Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, AstraZeneca, Pfizer Inc, Merck & Co., Inc., Genentech USA, Inc. and MannKind Corporation among others.

Why Purchase the Report?
• To visualize the global aerosol delivery device market segmentation based on product, application, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of aerosol delivery device market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global aerosol delivery device market report would provide approximately 62 tables, 58 figures and 184 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies